[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479554":3},{"organization":4,"outcomesModule":7,"designInfo":67,"detailedDescription":11,"studyPopulation":70,"armGroups":71,"interventions":89,"overallOfficials":111,"centralContacts":115,"locations":121,"responsibleParty":155,"collaborators":157,"id":160,"slug":11,"hasResults":161,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":11,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":11,"studyType":172,"phases":11,"briefSummary":173,"conditions":174,"keywords":11,"overallStatus":124,"whyStopped":11,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"University of Zurich","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":29,"otherOutcomes":11},[9,13,15,17,19,21,23,25,27],{"measure":10,"description":11,"timeFrame":12},"MR: multi-parameter mapping (MPM)",null,"Once during visit 2 (1-2 weeks after visit 1)",{"measure":14,"description":11,"timeFrame":12},"MR: quantitative susceptibility mapping (QSM)",{"measure":16,"description":11,"timeFrame":12},"Resting-state fMRI (brain and brainstem\u002Fspinal cord)",{"measure":18,"description":11,"timeFrame":12},"MR: whole-brain structural scans",{"measure":20,"description":11,"timeFrame":12},"MR: routine clinical scans",{"measure":22,"description":11,"timeFrame":12},"MR spectrosocpy",{"measure":24,"description":11,"timeFrame":12},"MR: diffusion imaging",{"measure":26,"description":11,"timeFrame":12},"MR: axial T2*w sequence",{"measure":28,"description":11,"timeFrame":12},"Task-fMRI",[30,33,36,38,42,45,47,49,51,53,55,58,61,64],{"measure":31,"description":11,"timeFrame":32},"Migraine patients: number of migraine attacks, intensity of migraine attacks (intensity 0 - 10), duration, accompanying symptoms, Migraine diary","Once during visit 1 (1-2 weeks prior to visit 2)",{"measure":34,"description":35,"timeFrame":32},"Migraine patients: Headache-attributed restriction, disability, social handicap and impaired participation (HARDSHIP) questionnaire","Modified questionnaire including personal and socio-demographic, diagnostic questions related to migraine, and enquiry into headache-related burden without strict scale",{"measure":37,"description":11,"timeFrame":32},"Migraine\u002F epilepsy\u002F visual snow syndrome patients: recording of possible other headache disorders and medication overuse",{"measure":39,"description":40,"timeFrame":41},"HADS questionnaire (Hospital anxiety and depression scale)","0-42, higher score \\> higher probability of anxiety\u002F depression","Once during visit 1 (1-2 weeks prior to visit 2) for patients and once for healthy participants at MRI visit (1-2 weeks after inclusion into study)",{"measure":43,"description":11,"timeFrame":44},"Acute medication","Once during visit 1 for patients (1-2 weeks prior to visit 2) and once for healthy participants at MRI visit (1-2 weeks after inclusion into study)",{"measure":46,"description":11,"timeFrame":32},"Epilepsy patients: diagnosis and classification according to ILAE",{"measure":48,"description":11,"timeFrame":32},"Epilepsy patients: current anticonvulsant medication",{"measure":50,"description":11,"timeFrame":32},"Epilepsy patients: seizure frequency",{"measure":52,"description":11,"timeFrame":32},"Epilepsy patients: analysis of previous EEG examinations with determination of the epileptic focus (hemisphere, localization)",{"measure":54,"description":11,"timeFrame":32},"Epilepsy patients: analysis of previous EEG examinations with qualitative assessment of the EEG to determine the type of epilepsy-specific abnormalities",{"measure":56,"description":57,"timeFrame":32},"Migraine patients: documentation of previous therapy attempts","Which type of therapy (medication, behavioral therapy or neuromodulation)",{"measure":59,"description":60,"timeFrame":32},"Epilepsy patients: documentation previous therapy attempts","Which type of therapy (medication, surgical intervention or neurostimulation)",{"measure":62,"description":63,"timeFrame":12},"Visual snow syndrome: Puledda Questionnaire","The higher the score, the higher the impact of visual snow",{"measure":65,"description":66,"timeFrame":12},"Migraine: Dizziness Handicap Inventory (DHI)","Score from 0-100, the higher the score, the higher the vertigo impact",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":68,"timePerspective":69,"maskingInfo":11},"COHORT","PROSPECTIVE","The participants will be recruited from the primary care clinics as well as from referring physicians or other clinics.\n\nHealthy controls will be recruited via public announcements and via flyers distributed at a primary care clinic and two universities.",[72,80,83,86],{"label":73,"type":11,"description":11,"interventionNames":74},"Healthy participants",[75,76,77,78,79],"Diagnostic Test: Structural MRI","Diagnostic Test: Quantitative MRI","Diagnostic Test: Diffusion MRI","Diagnostic Test: fMRI","Diagnostic Test: MR Spectroscopy",{"label":81,"type":11,"description":11,"interventionNames":82},"Patients with migraine",[75,76,77,78,79],{"label":84,"type":11,"description":11,"interventionNames":85},"Patients with drug resistent epilepsy",[75,76,77,78,79],{"label":87,"type":11,"description":11,"interventionNames":88},"Patients with visual snow syndrome",[75,76,77,78,79],[90,95,99,103,107],{"type":91,"name":92,"description":93,"armGroupLabels":94,"otherNames":11},"DIAGNOSTIC_TEST","Structural MRI","We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\\*-weighted sequences",[73,84,81,87],{"type":91,"name":96,"description":97,"armGroupLabels":98,"otherNames":11},"Quantitative MRI","We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).",[73,84,81,87],{"type":91,"name":100,"description":101,"armGroupLabels":102,"otherNames":11},"Diffusion MRI","We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.",[73,84,81,87],{"type":91,"name":104,"description":105,"armGroupLabels":106,"otherNames":11},"fMRI","We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.",[73,84,81,87],{"type":91,"name":108,"description":109,"armGroupLabels":110,"otherNames":11},"MR Spectroscopy","We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.",[73,84,81,87],[112],{"name":113,"affiliation":5,"role":114},"Patrick Freund, Prof. Dr. med. Dr. rer. nat.","PRINCIPAL_INVESTIGATOR",[116],{"name":117,"role":118,"phone":119,"phoneExt":11,"email":120},"Lynn Farner, MSc","CONTACT","+41 44 510 72 08","lynn.farner@balgrist.ch",[122,140],{"facility":123,"status":124,"city":125,"state":11,"zip":126,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":134,"contacts":135},"Klinik Lengg","RECRUITING","Zurich","8008","Switzerland","CH",{"type":130,"coordinates":131},"Point",[132,133],8.55,47.36667,{"lat":133,"lon":132},[136],{"name":137,"role":118,"phone":138,"phoneExt":11,"email":139},"Lukas Imbach, PD Dr. med.","+41 44 387 63 02","lukas.imbach@kliniklengg.ch",{"facility":141,"status":124,"city":125,"state":11,"zip":142,"country":127,"countryCode":128,"cosmosGeoPoint":143,"geoPoint":145,"contacts":146},"University Hospital Zurich","8091",{"type":130,"coordinates":144},[132,133],{"lat":133,"lon":132},[147,151],{"name":148,"role":118,"phone":149,"phoneExt":11,"email":150},"Lars Michels, PD Dr.","+41 44 255 49 65","lars.michels@usz.ch",{"name":152,"role":118,"phone":153,"phoneExt":11,"email":154},"Heiko Pohl, Dr. med.","+41 44 255 55 11","heiko.pohl@usz.ch",{"type":156,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[158],{"name":159,"class":6},"Balgrist University Hospital","100479554",false,"NCT05524493","High-field MR Imaging in Migraine, Visual Snow and Epilepsy","Inclusion Criteria:\n\nPatients:\n\n* Patient must be able to read and sign the informed consent form\n* Stable prophylactic medication for 2 months prior to MRI\n* At leat one of the two criteria applies:\n* Patients diagnosed with migraine (with or without aura, episodic or chronic). Diagnosis is ensured by clinical interview (at least 8 weeks prior to MRI). Also, patients complete a migraine questionnaire (HARDSHIP) (at least 8 weeks before MRI). Migraine frequency ≥ 2 migraine attacks\u002Fmonth.\n* Patients with drug resistent epilepsy accroding to ILAE crtieria\n* Patients with diagnoses of Visual snow syndrome\n\nHealthy participants;\n\n* No migraine (validated by questionnaire) or epilepsy\n* Participants must be able to read and sign the informed consent form\n\nExclusion Criteria:\n\n* Treatment of migraine disease with Botox within \\\u003C 4 months before baseline and during the study period\n* Pregnant or breastfeeding women\n* Intention during the course of the trial to become pregnant\n* Women with bilateral ovariectomy, with or without hysterectomy, and postmenopausal women (\\>2 years of age) are not considered childbearing.\n* Other clinically significant comorbidities (e.g., renal insufficiency, hepatic dysfunction, cardiovascular disease, etc.),\n* Known or suspected noncompliance with the protocol, drug or alcohol abuse,\n* Patient's inability to follow trial procedures, e.g., due to language problems, mental illness, dementia, etc.,\n* Prior participation in the clinical trial\n* Enrolment of the investigator, his\u002F her family members, employees and other dependent persons of the test personnel\n* Metallic objects in the body (e.g., splinters, MR incompatible implants).\n* Pacemaker\n* Claustrophobia\n* Obesity (body mass index \\> 35 kg\u002Fm2)",true,"ALL","18 Years","65 Years",{"count":170,"type":171},200,"ESTIMATED","OBSERVATIONAL","In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.\n\nMigraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.",[175,176,177],"Migraine","Epilepsy","Visual Snow Syndrome","2025-10-02",{"date":180,"type":181},"2025-10-08","ACTUAL",{"date":183,"type":181},"2025-03-01",{"date":185,"type":171},"2026-06-30",{"name":5,"class":6},2]